Agios Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of unusually large options trading activity on Tuesday. Investors purchased 4,672 call options on the company. This represents an increase of approximately 1,311% compared to the average daily volume of 331 call options.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new position in Agios Pharmaceuticals during the 4th quarter worth $25,000. Assetmark Inc. raised its position in shares of Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals during the first quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at $49,000. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at $79,000.

Wall Street Analyst Weigh In

A number of research firms have commented on AGIO. Bank of America boosted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright cut their target price on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 20th. The Goldman Sachs Group boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. JPMorgan Chase & Co. decreased their price target on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. Finally, Truist Financial raised their price target on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $42.56.

Agios Pharmaceuticals Trading Up 13.5%

NASDAQ AGIO traded up $5.05 on Tuesday, hitting $42.44. 1,308,738 shares of the company were exchanged, compared to its average volume of 1,028,898. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The firm has a 50 day moving average of $30.43 and a two-hundred day moving average of $29.41. The company has a market cap of $2.52 billion, a P/E ratio of -5.87 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. The business’s revenue was up 137.7% compared to the same quarter last year. Research analysts anticipate that Agios Pharmaceuticals will post -6.28 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.